Blockchain Registration Transaction Record

Clene Announces $10 Million Debt Facility for CNM-Au8 Treatment Development

Clene Inc. (NASDAQ: CLNN) secures $10 million debt facility to support the development of its CNM-Au8 treatment for ALS and neurodegenerative diseases, addressing FDA data requirements for regulatory approval.

Clene Announces $10 Million Debt Facility for CNM-Au8 Treatment Development

This news matters as it highlights Clene's strategic financial move to secure funding for the development of its CNM-Au8 treatment for ALS and neurodegenerative diseases, potentially impacting the future of neurological disease treatment.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x352dc2b6e4d2fe44ed749567bdbcc1b6501594a60b0eff3962ee9ae8f1587876
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintyawnyJXd-a8db4a0c12fccb51e0f79a8608e83095